What is the difference between generic DastraZeneca and cycloserine?

Cycloserine (Cycloserine) has been used for the treatment of drug-resistant tuberculosis diseases around the world for many years. Its original product and generic versions produced in many countries are widely used, including the cycloserine generic produced in South Korea. Daslecon (Daslecon) accounts for a high proportion of clinical use. Although the main ingredient of both is exactly the same, which is cycloserine, there are differences in the production system, quality supervision, accessibility and price system, which leads to the question often asked by patients: "What is the difference between original research and generics?"

In terms of ingredients, there is no difference between dastralica and the original drug. They both use cycloserine as the main active drug and have the same mechanism of action. However, due to different manufacturing companies, there may be slight differences in preparation excipients, tableting processes, dissolution characteristics, etc. These differences will affect drug stability, taking experience or absorption speed, but will not change the core efficacy. Korean pharmaceutical companies have mature quality systems in the field of generic drug production and continue to export to many countries, making them one of the more reliable sources of generic drugs.

In terms of quality supervision, originator drugs usually have complete quality standards established by their research and development institutions, while generic drugs such as DatraZeneca are reviewed by local regulatory agencies in South Korea and pass the quality assessment of the multi-national procurement system. Overseas guidelines point out that as long as generic drugs meet consistent quality standards, there will generally be no difference in efficacy in clinical use. Thus, in clinical real-world settings, physicians often make choices based on accessibility, patient affordability, and stability of supply.

Price is one of the most obvious differences between the two. The price of the original drug is relatively high, but South Korea's DastraZeneca has more advantages in production costs and export models, and has shown a higher cost performance in many countries, making it an important guarantee for many patients' long-term compliance. The price difference does not represent a difference in efficacy, but has more to do with the brand, production system and market strategy.

References: https://en.wikipedia.org/wiki/Cycloserine